Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus DEXAMETHASONE.
ACTICORT vs DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category D/X
Corticosteroid
Corticosteroid